Related Experiment Videos
Everolimus for stent-based intracoronary applications
Eberhard Grube1, Lutz Buellesfeld
1Heart-Center Siegburg, Siegburg, Germany.
Reviews in Cardiovascular Medicine
|June 9, 2004
Summary
Everolimus-eluting stents show promise for treating coronary heart disease by significantly reducing neointimal proliferation. Clinical trials indicate a favorable safety profile, comparable to existing drug-eluting stents.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Biomaterials Science
Background:
- Everolimus is a potent anti-proliferative and immunosuppressive agent, superior to sirolimus in local tissue absorption and cellular activity.
- Drug-eluting stents (DES) are crucial for preventing restenosis after percutaneous coronary intervention.
Purpose of the Study:
- To evaluate the safety and feasibility of everolimus-eluting stents (EES) in patients with coronary lesions.
- To assess the efficacy of EES in suppressing neointimal hyperplasia compared to bare-metal stents.
Main Methods:
- Preclinical studies and clinical trials (FUTURE I and II) involving bioabsorbable-PLA-polymer-coated S-Stents.
- Intracoronary elution of everolimus for drug delivery in coronary arteries.
- Follow-up assessments for safety (stent thrombosis, malapposition) and efficacy (neointimal proliferation).
Main Results:
- Acceptable safety profile observed in FUTURE I and II trials, with no stent thrombosis or late malapposition.
- Remarkable reduction in neointimal proliferation with EES compared to bare-metal stents.
- Early evidence suggests EES efficacy is comparable to sirolimus-eluting stents (Cypher).
Conclusions:
- Everolimus-eluting stents demonstrate safety and efficacy in treating coronary lesions.
- EES represent a promising new option in the field of drug-eluting stents for coronary heart disease.
- Further pivotal trials (FUTURE III and IV) are planned to confirm efficacy and compare with existing DES.